HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adrien Grenier Selected Research

GSK621

1/2022AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia.
6/2015Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Adrien Grenier Research Topics

Disease

3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2022 - 06/2015
2Neoplasms (Cancer)
11/2021 - 01/2018
1Oncogene Addiction
01/2022
1Graft vs Host Disease (Graft-Versus-Host Disease)
11/2021
1Metabolic Diseases (Metabolic Disease)
01/2018
1Residual Neoplasm
03/2016

Drug/Important Bio-Agent (IBA)

2GSK621IBA
01/2022 - 06/2015
1trametinibIBA
01/2022
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2022
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
11/2021
1AMP-Activated Protein KinasesIBA
01/2018
1Rituximab (Mabthera)FDA Link
03/2016
1Mechanistic Target of Rapamycin Complex 1IBA
06/2015

Therapy/Procedure

1Therapeutics
01/2022
1Hematopoietic Stem Cell Transplantation
11/2021
1Transplantation
11/2021